deltatrials
Completed PHASE1/PHASE2 NCT00286806

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy

Sponsor: Ascenta Therapeutics

Conditions Hormone Refractory Prostate Cancer
Interventions AT-101
Updated 6 times since 2017 Last updated: Aug 20, 2010 Started: Dec 31, 2005 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This PHASE1/PHASE2 trial investigates Hormone Refractory Prostate Cancer and is currently completed. Ascenta Therapeutics leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ascenta Therapeutics
Data source: Ascenta Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Greenbrae, United States
  • • Madison, United States
  • • Memphis, United States
  • • New Haven, United States